Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.
Immune-Onc, a US-based immuno-oncology therapy developer partly based on University of Texas research, has received more than $33m in series B funding from investors including Stanford-StartX fund.
VC firm Northern Light Venture Capital and healthcare-focused investment firm Vivo Capital both participated in the series B round.
Founded in 2015, Immune-Onc is developing immunotherapies for cancer that focus on infiltrating tumours and unwinding the suppression of the patient’s immune system.
The company’s lead program, IO-202, will primarily target…
